secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001654954-25-006282
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences receives Nasdaq delisting notice for insufficient stockholders' equity
--------------------------------------------------------------------------------

- Stockholders' equity of $1,752,885 as of March 31, 2025, below Nasdaq's $2.5M minimum.
- Nasdaq letter received May 27, 2025; company has until July 11, 2025 to submit a compliance plan.
- If plan accepted, company has until November 23, 2025 to regain compliance.
- Failure could lead to delisting; company intends to take measures to regain compliance, but no assurance given.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495425006282/0001654954-25-006282-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495425006282/endra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-006282

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer